Seek Returns logo

AZN vs. JPM: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at AZN and JPM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, JPM is a standard domestic listing.

SymbolAZNJPM
Company NameAstraZeneca PLCJPMorgan Chase & Co.
CountryUnited KingdomUnited States
GICS SectorHealth CareFinancials
GICS IndustryPharmaceuticalsBanks
Market Capitalization247.43 billion USD810.90 billion USD
ExchangeNasdaqGSNYSE
Listing DateMay 12, 1993March 17, 1980
Security TypeADRCommon Stock

Historical Performance

This chart compares the performance of AZN and JPM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

AZN vs. JPM: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolAZNJPM
5-Day Price Return1.96%1.46%
13-Week Price Return14.68%13.13%
26-Week Price Return2.26%5.60%
52-Week Price Return-9.33%36.13%
Month-to-Date Return5.69%-0.45%
Year-to-Date Return14.33%23.02%
10-Day Avg. Volume0.98M7.05M
3-Month Avg. Volume1.47M8.43M
3-Month Volatility22.26%16.50%
Beta1.011.15

Profitability

Return on Equity (TTM)

AZN

19.84%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

AZN’s Return on Equity of 19.84% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.

JPM

16.16%

Banks Industry

Max
26.37%
Q3
15.92%
Median
12.25%
Q1
8.69%
Min
0.15%

In the upper quartile for the Banks industry, JPM’s Return on Equity of 16.16% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

AZN vs. JPM: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Net Profit Margin (TTM)

AZN

14.68%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

AZN’s Net Profit Margin of 14.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

JPM

33.26%

Banks Industry

Max
54.20%
Q3
35.70%
Median
28.97%
Q1
22.53%
Min
6.98%

JPM’s Net Profit Margin of 33.26% is aligned with the median group of its peers in the Banks industry. This indicates its ability to convert revenue into profit is typical for the sector.

AZN vs. JPM: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Operating Profit Margin (TTM)

AZN

20.04%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

AZN’s Operating Profit Margin of 20.04% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

JPM

41.23%

Banks Industry

Max
63.35%
Q3
44.59%
Median
37.24%
Q1
28.25%
Min
13.37%

JPM’s Operating Profit Margin of 41.23% is around the midpoint for the Banks industry, indicating that its efficiency in managing core business operations is typical for the sector.

AZN vs. JPM: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Profitability at a Glance

SymbolAZNJPM
Return on Equity (TTM)19.84%16.16%
Return on Assets (TTM)7.76%1.32%
Net Profit Margin (TTM)14.68%33.26%
Operating Profit Margin (TTM)20.04%41.23%
Gross Profit Margin (TTM)82.07%--

Financial Strength

Current Ratio (MRQ)

AZN

0.86

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

AZN’s Current Ratio of 0.86 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

JPM

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

For the Banks industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

AZN vs. JPM: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Banks industry benchmarks.

Debt-to-Equity Ratio (MRQ)

AZN

0.73

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

AZN’s Debt-to-Equity Ratio of 0.73 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

JPM

3.03

Banks Industry

Max
4.75
Q3
2.62
Median
1.02
Q1
0.39
Min
0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Banks industry.

AZN vs. JPM: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Banks industry benchmarks.

Interest Coverage Ratio (TTM)

AZN

9.51

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

AZN’s Interest Coverage Ratio of 9.51 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

JPM

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Banks industry.

AZN vs. JPM: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Financial Strength at a Glance

SymbolAZNJPM
Current Ratio (MRQ)0.86--
Quick Ratio (MRQ)0.67--
Debt-to-Equity Ratio (MRQ)0.733.03
Interest Coverage Ratio (TTM)9.51--

Growth

Revenue Growth

AZN vs. JPM: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

AZN vs. JPM: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

AZN

2.00%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

AZN’s Dividend Yield of 2.00% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

JPM

1.94%

Banks Industry

Max
10.27%
Q3
5.83%
Median
3.81%
Q1
2.50%
Min
0.00%

JPM’s Dividend Yield of 1.94% is in the lower quartile for the Banks industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.

AZN vs. JPM: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Dividend Payout Ratio (TTM)

AZN

59.51%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

AZN’s Dividend Payout Ratio of 59.51% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

JPM

27.49%

Banks Industry

Max
147.07%
Q3
80.55%
Median
54.40%
Q1
35.71%
Min
0.00%

JPM’s Dividend Payout Ratio of 27.49% is in the lower quartile for the Banks industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.

AZN vs. JPM: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Dividend at a Glance

SymbolAZNJPM
Dividend Yield (TTM)2.00%1.94%
Dividend Payout Ratio (TTM)59.51%27.49%

Valuation

Price-to-Earnings Ratio (TTM)

AZN

29.72

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

A P/E Ratio of 29.72 places AZN in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

JPM

14.18

Banks Industry

Max
20.05
Q3
12.65
Median
10.21
Q1
7.54
Min
2.74

A P/E Ratio of 14.18 places JPM in the upper quartile for the Banks industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

AZN vs. JPM: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Price-to-Sales Ratio (TTM)

AZN

4.36

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

AZN’s P/S Ratio of 4.36 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

JPM

2.90

Banks Industry

Max
5.06
Q3
2.98
Median
2.24
Q1
1.59
Min
0.45

The P/S Ratio is often not a primary valuation tool in the Banks industry.

AZN vs. JPM: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Price-to-Book Ratio (MRQ)

AZN

4.74

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

AZN’s P/B Ratio of 4.74 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

JPM

2.26

Banks Industry

Max
2.18
Q3
1.36
Median
1.09
Q1
0.81
Min
0.20

At 2.26, JPM’s P/B Ratio is at an extreme premium to the Banks industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

AZN vs. JPM: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Banks industry benchmarks.

Valuation at a Glance

SymbolAZNJPM
Price-to-Earnings Ratio (TTM)29.7214.18
Price-to-Sales Ratio (TTM)4.362.90
Price-to-Book Ratio (MRQ)4.742.26
Price-to-Free Cash Flow Ratio (TTM)30.134.52